1LP.F - Lansen Pharmaceutical Holdings Limited

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Lansen Pharmaceutical Holdings Limited

228 Xinfeng Road
Gaoqiao Industrial Park Haishu District
Ningbo 315174
China
86 574 8804 6316
http://www.lansen.com.cn

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees622

Key Executives

NameTitlePayExercisedYear Born
Mr. Li ChenExec. MD, CEO & Exec. Director575.6kN/A1962
Mr. Kai Fai PangFin. Mang. & Company Sec.N/AN/AN/A
Mr. Yu ZhaoGroup HR DirectorN/AN/A1973
Mr. Jianshe NanHead of Bus. Devel.N/AN/A1966
Mr. Hua LiHead of Fin. Management CentreN/AN/A1985
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology, dermatology, and other pharmaceuticals in the People's Republic of China and internationally. It operates through Pharmaceuticals, Medical Cosmetics Products, and Healthcare Products segments. The company's specialist medicines comprise Pafulin, which includes total glucosides of white peony capsules; Hepai, a leflunomide tablet; and mycophenolate mofetil dispersible capsules. It also offers Chinese medicine generic drugs; IVD products; health foods; medical cosmetics; and healthcare products, as well as natural plant extracts. The company was founded in 2001 and is headquartered in Ningbo, the People's Republic of China. Lansen Pharmaceutical Holdings Limited is a subsidiary of Cathay International Pharma Manufacture and Distribution (China) Limited.

Corporate Governance

Lansen Pharmaceutical Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.